Yoon & Yang LLC has shown steep growth since Managing Partner Lee Myung-soo took office, with last year's annual revenue topping 301.2 billion won. Observers said results in financial regulation and litigation for corporations, along with aggressive talent recruitment and a client-first strategy, drove the gains.
According to legal sources on the 27th, based on National Tax Service value-added taxes filings, Yoon & Yang posted revenue of 281.2 billion won last year. Including revenue from its sister firm and overseas offices, total revenue rises to 301.2 billion won. Compared with 2024 (250 billion won), revenue grew more than 20%. It was up 35% from 2023 (208.2 billion won).
Yoon & Yang's revenue per lawyer (RPL) for Korean attorneys last year was 762 million won. It is the industry's top tier. This is the highest level in the law firm industry. The consensus is that the firm succeeded in achieving both productivity and profitability.
Yoon & Yang's string of large mandates in financial regulation and litigation for corporations is also seen as fueling the revenue surge. For example, in 2025, the firm, representing Asiana Airlines, won a suit over the return of a 250 billion won deposit, and in a case related to the Samsung C&T–Cheil Industries merger, it defended Samsung C&T management and secured acquittals at all instances. In suits over misselling of equity-linked securities (ELS), it represented commercial banks and won full dismissal of investors' claims, among other results.
It is also delivering results in antitrust, intellectual property (IP), serious industrial accident response, and mergers and acquisitions (M&A). Notably, it handled major corporate advisory matters including a roughly 20 trillion won comprehensive share-swap acquisition transaction between Naver and Dunamu, the sale of Hyosung Chemical's neochem business unit, and advising Hanwha Life Insurance on its acquisition of U.S. securities firm Velocity.
In addition, it is making its presence felt in trade secret and patent disputes, including representing Medytox in the appellate case over trade secret infringement related to Botox (botulinum toxin) against Daewoong Pharmaceutical.
Yoon & Yang attributed the sharp revenue growth last year to "the effectiveness of a client-first approach, aggressive talent recruitment, and differentiated, customized strategies since 2024, when Managing Partner Lee took office."
Lee is widely regarded in legal circles as a "finance expert." After passing the 39th bar exam and completing the Judicial Research and Training Institute (29th class), Lee began working as an attorney at the Financial Supervisory Service in 2000. As the FSS's first in-house attorney, Lee spent 10 years in key posts including the Dispute Mediation Bureau, the Disclosure Review Office as a senior investigator, and as Head of Team in the Legal Affairs Office and the Corporate Disclosure Bureau.
Lee joined Yoon & Yang in 2010 and led the financial regulation team. Lee oversaw advisory and investigation response work for financial institutions in matters such as the Lime scandal's private fund misselling and obligations to establish internal control standards.
Lee said, "The significant growth Yoon & Yang has achieved over the past two years is the result of attorneys and other experts building a sustainable growth structure based on the management's strategic plan." Lee added, "Under a client-first policy, we will enhance expertise and service quality by recruiting top talent."